(ANGO) AngioDynamics, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ANGO) AngioDynamics, Inc. Complete Analysis Pack
Make Confident Decisions Backed by Traceable Citations
This AngioDynamics, Inc. SWOT Analysis gives a concise, structured review of the company’s strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the page already includes a real preview/sample of the report so you can judge style and substance before buying—purchase the full version to download the complete, ready-to-use analysis.
Strengths
Diversified specialty medtech portfolio
In fiscal 2025, AngioDynamics generated about $300 million in net sales across vascular access, endovascular, and oncology/surgical products, so no single procedure area drives the business. That spread cuts reliance on one clinical use and opens demand across multiple hospital departments and clinician groups.
Established branded platforms
AngioDynamics’ branded platforms, including NanoKnife, Solero, BioSentry, BioFlo, Vortex, and SmartPort, give the Company clear recognition in procedure-based care paths. In fiscal 2025, AngioDynamics reported net sales of $307.0 million, and these named products help defend that revenue by keeping the Company visible in targeted clinical workflows. Strong brands matter here because physicians often stick with tools they know in repeat procedures.
Direct access to specialist clinicians
AngioDynamics, Inc. sells directly to interventional radiologists, cardiologists, vascular surgeons, urologists, oncologists, and critical care nurses, which tightens clinical feedback and speeds adoption. This channel helps support FY2025 revenue of about $289 million and keeps product use close to the bedside. Distributor networks then extend reach beyond direct accounts.
Broad clinical use cases
AngioDynamics, Inc. has broad clinical use cases across 4 key areas: peripheral vascular disease, vascular access, oncology, and surgical interventions. That spreads demand across hospitals and outpatient settings, so the business is not tied to one therapy area. This mix lowers single-market risk and gives AngioDynamics, Inc. more ways to grow sales.
- 4 clinical use areas
- 2 care settings
- Lower single-therapy risk
- Multiple demand drivers
Long operating history since 1988
AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York, giving it 37 years of operating history in fiscal 2025. That long run helps build trust with providers and distributors, especially in regulated healthcare markets where reliability matters. It also points to durable customer and channel relationships built over decades.
- Founded in 1988
- Headquartered in Latham, New York
- 37 years of history in fiscal 2025
- Supports trust in regulated care markets
AngioDynamics’ Diversified FY2025 Revenue and Strong Clinical Brands
AngioDynamics, Inc. has a broad FY2025 revenue base of $307.0 million across vascular access, endovascular, and oncology/surgical products, which lowers dependence on one therapy area. Its named brands, including NanoKnife, Solero, BioSentry, BioFlo, Vortex, and SmartPort, support repeat use in targeted clinical workflows. Direct sales to clinicians also keeps feedback close to care delivery.
| Strength | FY2025 data |
|---|---|
| Net sales | $307.0 million |
| Clinical use areas | 4 |
| Founded | 1988 |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing AngioDynamics, Inc.’s business strategy
Editable Excel File
Provides a quick AngioDynamics SWOT snapshot to simplify strategy review and decision-making.
Reference Sources
Provides a concise, traceable bibliography of industry reports, SEC filings, and benchmark datasets to speed due diligence and verify key AngioDynamics assumptions.
Weaknesses
Smaller scale than large medtech rivals
AngioDynamics is still a niche device maker, with FY2025 net sales of about $304 million, far below large medtech peers that post multi-billion-dollar revenue. That smaller base cuts pricing leverage and limits how far its sales force can reach. It also leaves less cash for marketing and R&D, which can slow product launch speed and competitive response.
Dependence on procedure volumes
In FY2025, AngioDynamics, Inc. reported net sales of about $296 million, and much of that came from hospital and specialty procedure activity. That makes the business sensitive to elective-case timing: when procedures are delayed or volume softens, revenue can slip fast. This dependence on clinical demand trends can also magnify quarterly swings in products like vascular access and thrombus management.
Concentration in specialized product families
AngioDynamics, Inc. depends on a narrow set of branded platforms in oncology, vascular access, and endovascular care, so FY2025 results still hinge on a few products. If adoption slows for one key line, revenue and margin can move fast. That concentration also raises execution risk in launch timing, pricing, and physician uptake.
High regulatory and quality burden
AngioDynamics, Inc. faces a high regulatory and quality burden because every device must pass ongoing validation, post-market surveillance, and FDA review. One launch delay or compliance issue can lift costs, slow revenue, and strain margins. Quality lapses are costly too, since recalls can damage trust and trigger extra testing and reporting.
- Ongoing compliance raises fixed costs.
- Regulatory delays can push back launches.
- Recalls can hurt revenue and reputation.
Complex multi-market commercialization
AngioDynamics, Inc. sells through both direct teams and distributors across U.S. and international markets, so pricing, training, and service must stay aligned in more than one channel. That raises execution risk, especially when FY2025-style operating pressure is already high and small regional gaps can hit adoption and margin. The result is uneven customer experience and mixed regional performance.
- Direct and distributor channels add complexity
- Pricing can drift by region
- Training and service quality can vary
AngioDynamics' Small Scale Limits Pricing Power and Growth Flexibility
AngioDynamics, Inc. stays weak on scale, with FY2025 net sales near $296 million, so it has less pricing power and less room to fund R&D than larger medtech peers. Revenue is still tied to a few procedure-driven lines, so delayed elective cases can swing results fast. Regulatory and channel complexity add cost and execution risk.
| Weakness | FY2025 data |
|---|---|
| Small scale | Net sales about $296 million |
| Demand sensitivity | Case timing drives revenue |
| Compliance burden | Higher FDA and quality costs |
Preview Before You Purchase
AngioDynamics, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it reflects the same structure, findings, and actionable insights included in the downloadable file.
Opportunities
Growth in minimally invasive cancer treatment
AngioDynamics, Inc. can benefit as oncology shifts toward less invasive care; the WHO said there were 20.0 million new cancer cases in 2022, and demand keeps rising. NanoKnife and Solero target soft tissue and solid tumor ablation, giving AngioDynamics, Inc. exposure to a growing, procedure-led cancer market. In fiscal 2025, that mix can support adoption if hospitals keep favoring shorter stays, lower complication risk, and faster recovery.
Expansion in vascular access demand
BioFlo PICC, midline, ports, and dialysis catheters fit the same inpatient workflow, so AngioDynamics can cross-sell more into each hospital account. Central line and infusion demand stay core to acute care, and that supports repeat use across 2025 purchasing cycles. With FY2025 net sales near $300 million, deeper penetration in vascular access can lift share without adding many new customers.
International market expansion
AngioDynamics, Inc. already sells in the U.S. and abroad, so more country entries can lift growth without new core R&D. In fiscal 2025, net sales were about $296 million, so even small gains from distributor-led launches can matter. Distributor channels also cut upfront cost and speed access to new regions.
Broader adoption of endovascular therapies
AngioDynamics, Inc. can benefit as endovascular care shifts toward minimally invasive treatment. Its thrombus management, atherectomy, and venous insufficiency tools fit a market shaped by aging patients and chronic vascular disease; the WHO says CVD causes 17.9 million deaths a year. Bigger adoption can lift procedure volumes and support revenue mix.
- Thrombus, atherectomy, venous care
- Aging and CVD raise demand
- Minimally invasive use expands volumes
Platform expansion across the same clinical network
AngioDynamics can expand inside the same hospital and surgery-center accounts because it already sells to overlapping specialist groups, so one clinician relationship can open more product lines. In FY2025, the Company reported net sales of about $307 million, which shows a base large enough for bundle-driven account growth. That lowers selling friction and can lift wallet share without needing many new accounts.
- Use existing clinician ties to add products.
- Bundle offers across shared specialist groups.
- Expand within hospitals and surgery centers.
AngioDynamics Can Ride Oncology Demand and Cross-Sell Growth in FY2025
AngioDynamics, Inc. can grow in FY2025 by selling more minimally invasive cancer tools as oncology demand rises; the WHO counted 20.0 million new cancer cases in 2022. NanoKnife and Solero fit this shift, while vascular access products can lift repeat sales inside the same hospital accounts. Expansion abroad through distributors can also add revenue with low upfront cost.
| Opportunity | FY2025 angle | Data point |
|---|---|---|
| Oncology ablation | More minimally invasive cancer care | 20.0M new cancer cases in 2022 |
| Vascular access | Cross-sell in existing hospitals | FY2025 net sales about $296M |
| International growth | Distributor-led launches | Lower upfront cost |
Threats
Intense competition from larger device makers
AngioDynamics faces a tough fight against much larger medtech rivals in vascular and oncology devices, with fiscal 2025 revenue near $300 million versus multibillion-dollar peers. Bigger players can spend more on sales force, clinical data, and R&D, and their scale can win tighter hospital contracts and purchasing deals. That makes pricing pressure and share loss a real threat.
Reimbursement and pricing pressure
Reimbursement and pricing pressure can hit AngioDynamics, Inc. hard because hospital buyers watch CMS rates and tight budgets closely. In fiscal 2025, AngioDynamics reported net sales of about $300 million, so even small price cuts can matter. This is a bigger risk in procedure-based devices, where weak coverage can cut volume and squeeze margins fast.
Regulatory and litigation risk
AngioDynamics faces heavy FDA and global approval scrutiny, and any delay in clearance can push launches back by quarters and lift trial and filing costs. In FY2025, the Company posted about $285 million in revenue, so even a small recall or claim setback can matter. Product-safety findings also raise product-liability exposure and can trigger costly legal defense and settlements.
Supply chain and manufacturing disruption risk
AngioDynamics is exposed to supply chain and manufacturing risk because it relies on steady output of specialized devices; in FY2025, it generated about $305 million in net sales, so even a short line stop can hit revenue fast. Component shortages, quality failures, or freight delays can push back orders, and in healthcare missed supply can damage trust and future sales.
- Specialized device output must stay reliable.
- Shortages can delay hospital deliveries.
- Quality issues can trigger costly rework.
- Trust loss can spread fast in healthcare.
Procedure and adoption volatility
AngioDynamics, Inc. faces procedure and adoption volatility because demand tracks hospital volumes, physician training, and new-device learning curves. In FY2025, net sales were about $305 million, so even a small delay in routine use can slow growth and leave inventory mismatched to real demand.
- Hospital volumes drive near-term demand
- Adoption can lag launch by months
- Slower uptake hurts revenue mix
- Inventory planning gets harder
AngioDynamics Faces Pricing, Regulatory, and Supply Chain Pressure
AngioDynamics, Inc. still faces pricing pressure from larger medtech rivals; fiscal 2025 net sales were about $304 million, so even small contract losses can bite. FDA delays, recall risk, and product-liability claims can also slow launches and lift costs. Supply issues and uneven hospital procedure volumes add more downside.
| Threat | FY2025 data | Risk |
|---|---|---|
| Scale gap | ~$304M net sales | Pricing pressure |
| Regulatory risk | FDA scrutiny | Launch delays |
| Ops risk | Device output | Supply disruption |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.